Tumor lesion glycolysis and tumor lesion proliferation for response prediction 
and prognostic differentiation in patients with advanced non-small cell lung 
cancer treated with erlotinib

Kahraman, Deniz; Holstein, Arne; Scheffler, Matthias; Zander, Thomas; Nogova, Lucia; Lammertsma, Adriaan A.; Boellaard, Ronald; Neumaier, Bernd; Dietlein, Markus; Wolf, Jürgen; Kobe, Carsten

doi:10.1097/RLU.0b013e3182639747

Local TagsRelease HistoryDetailsSummary

Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib

Kahraman, D., Holstein, A., Scheffler, M., Zander, T., Nogova, L., Lammertsma, A. A., et al. (2012). Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clinical Nuclear Medicine, 37(11), 1058-1064. doi:10.1097/RLU.0b013e3182639747.

Item is Released

show all hide all

Basic

show hide

Item Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-DA7A-7 Version Permalink: https://hdl.handle.net/11858/00-001M-0000-0026-DA7B-5

Genre: Journal Article

Files

show Files

Locators

show

Creators

show

hide

Creators:
Kahraman, Deniz¹, Author
Holstein, Arne¹, Author
Scheffler, Matthias¹, Author
Zander, Thomas², Author
Nogova, Lucia¹, Author
Lammertsma, Adriaan A.¹, Author
Boellaard, Ronald¹, Author
Neumaier, Bernd³, Author
Dietlein, Markus⁴, Author
Wolf, Jürgen¹, Author
Kobe, Carsten¹, Author

Affiliations:
1a Department for Nuclear Medicine, Center for Integrated Oncology Cologne, Bonn University Hospital of Cologne, 50924 Cologne, Germany b Center for Integrated Oncology Cologne Bonn, Germany c Department i for Internal Medicine, University Hospital of Cologne, Cologne, Germany d Department of Nuclear Medicine and PET Research, VU University Medical Center, Amsterdam, Netherlands, ou_persistent22
2Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663
3Radiochemistry, Scientific Services and Development, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149672
4Translational Neurocircuitry, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149668

Content

show

hide

Free keywords: -

Details

show

hide

Language(s): eng - English

Dates: Date issued: 2012

Publication Status: Issued

Pages: -

Publishing info: -

Table of Contents: -

Rev. Type: Peer

Identifiers: eDoc: 628390
DOI: 10.1097/RLU.0b013e3182639747

Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show

hide

Title: Clinical Nuclear Medicine

Source Genre: Journal

Creator(s):

Affiliations:

Publ. Info: -

Pages: - Volume / Issue: 37 (11) Sequence Number: - Start / End Page: 1058 - 1064 Identifier: ISSN: 03639762